Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-associated Oropharyngeal Cancer

B. S. Chera\(^1\), S. Kumar\(^2\), C. Shen\(^3\), R. J. Amdur\(^4\), R. Dagan\(^5\), J. Weiss\(^6\), J. Grilley-Olson\(^3\), A. Zanation\(^6\), T. Hackman\(^6\), J. Blumberg\(^3\), S. Patel\(^6\), B. Thorp\(^6\), M. Weissler\(^6\), N. C. Sheets\(^6\), W. M. Mendenhall\(^4\), and G. P. Gupta\(^2\)

\(^1\)Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, NC, \(^2\)The University of North Carolina, Chapel Hill, NC, \(^3\)University of North Carolina School of Medicine, Chapel Hill, NC, \(^4\)University of Florida College of Medicine, Gainesville, FL, \(^5\)University of Florida College of Medicine, Jacksonville, FL, \(^6\)University of North Carolina Hospitals, Chapel Hill, NC
Disclosure for Dr. Chera

• University of North Carolina School of Medicine
  • Employer

• Naveris:
  • Scientific Advisory Board with equity

• Research funding from
  • Burroughs Wellcome Fund
  • Dept of Defense
  • Susan G. Komen Foundation
  • North Carolina University Cancer Research Fund
Background

- Plasma circulating tumor HPV DNA (ctHPVDNA) is detected in a majority of HPV-OPSCC patients

- Potential biomarker of tumor burden and response kinetics

- *Can plasma ctHPVDNA be used to detect cancer recurrence?*

Cao H, …, Le QT, *IJROBP* 2012
Wang Y, …, Agrawal N *Sci Transl Med* 2015
Chera B, …, Gupta G *ASTRO* 2017
Gupta G, …, Chera B *ASTRO/ASCO* 2018
Multi-analyte Digital PCR (dPCR) Assay for ctHPVDNA

- Standardized multi-step analytical protocol to optimize specificity and sensitivity
- Distinguishes ctHPVDNA from native viral genomes
- Detects ctHPV-16, -18, -31, -33, and -35 (more high-risk strains coming)

Chera B, …, Gupta G ASTRO 2017
Gupta G, …, Chera B ASTRO/ASCO 2018
Method: Prospective Biomarker Trial

- 89 patients with biopsy-proven HPV-associated OPSCC
- All patients received definitive chemoradiation
- Blood specimen collection/analysis (~1000 blood samples)
  - 58/89 had pretreatment assessment (65%)
  - 89/89 had surveillance/posttreatment assessments (100%)
- Clinical surveillance
  - Every 2 - 4 months for years 1 - 2, every 6 months for years 3 – 5
  - Chest imaging every 6 months
  - Additional imaging was obtained if ctHPV DNA became detectable
- Events were defined as recurrence after the 3 month post-CRT PET/CT
70 out of 89 patients (79%) had undetectable ctHPVDNA during surveillance.

All 70 of these patients remain disease free (NPV = 100%).
19 out of 89 patients (21%) had a positive ctHPVDNA signal at one or more followup timepoints.

8 out of these 19 patients have developed biopsy-proven recurrence (PPV = 42%).

P < 0.0001 (two-tailed Fisher’s exact test)
N = 8

Surveillance

- 8 patients with biopsy-proven recurrence:
  - 0 local
  - 1 regional only
  - 3 regional and distant
  - 4 with distant

- All patients remain alive
- 3 patients are currently NED by imaging and blood tests (2 patients on immunotx, 1 post-chemo)

Detectable ctHPVDNA with Recurrence
11 patients had detectable ctHPVDNA but no recurrent disease evident on imaging.

4 patients spontaneously cleared their ctHPVDNA signal → immune effects?

The remaining 7 patients continue to be closely monitored.
Patient diagnosed with HPV+ OPC in 2015.

Blood test in June 2017 shows no abnormality detected.


MRI & PET scans in Oct detect recurrence in neck.

Remission after therapy.
3 month post-CRT
0/27 nodes positive
0 copies/ml

22 months post-CRT
96 copies/ml

28 months post-CRT
0 copies/ml

PET/CT
Bronch & FNA
6 weeks carbo/taxol
Conclusions

• A multi-analyte ctHPVDNA assay detects patients at risk of cancer recurrence
• None of the patients with undetectable ctHPVDNA during post-treatment surveillance developed disease recurrence (NPV = 100%, N=70).

Future Directions:
• Limit cross-sectional imaging to patients who are at greatest risk → reduced cost and radiation exposure
• Early detection may increase effectiveness of salvage therapy
• Possibility of more frequent monitoring
• Possible avoidance of invasive biopsy procedures for patients with radiographic correlate and detectable ctHPVDNA